SE9403846D0 - Small particle formation - Google Patents

Small particle formation

Info

Publication number
SE9403846D0
SE9403846D0 SE9403846A SE9403846A SE9403846D0 SE 9403846 D0 SE9403846 D0 SE 9403846D0 SE 9403846 A SE9403846 A SE 9403846A SE 9403846 A SE9403846 A SE 9403846A SE 9403846 D0 SE9403846 D0 SE 9403846D0
Authority
SE
Sweden
Prior art keywords
pct
date
small particle
particle formation
sec
Prior art date
Application number
SE9403846A
Other languages
English (en)
Swedish (sv)
Inventor
Sylvan Frank
Jan-Erik Loefroth
Levon Bostanian
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Priority to SE9403846A priority Critical patent/SE9403846D0/xx
Publication of SE9403846D0 publication Critical patent/SE9403846D0/xx
Priority to PCT/SE1995/001302 priority patent/WO1996014833A1/en
Priority to NZ295497A priority patent/NZ295497A/en
Priority to ES95938091T priority patent/ES2173204T3/es
Priority to US08/553,460 priority patent/US5780062A/en
Priority to SK559-97A priority patent/SK55997A3/sk
Priority to PL95320425A priority patent/PL320425A1/xx
Priority to DK95938091T priority patent/DK0788350T3/da
Priority to CZ971295A priority patent/CZ129597A3/cs
Priority to DE69525639T priority patent/DE69525639T2/de
Priority to AU38851/95A priority patent/AU700644B2/en
Priority to JP51597096A priority patent/JP4098827B2/ja
Priority to KR1019970703072A priority patent/KR970706799A/ko
Priority to EE9700214A priority patent/EE9700214A/xx
Priority to EP95938091A priority patent/EP0788350B1/en
Priority to AT95938091T priority patent/ATE213625T1/de
Priority to PT95938091T priority patent/PT788350E/pt
Priority to CA002203512A priority patent/CA2203512A1/en
Priority to HU9800181A priority patent/HUT77629A/hu
Priority to CN95196084A priority patent/CN1165478A/zh
Priority to BR9509720A priority patent/BR9509720A/pt
Priority to IL11587895A priority patent/IL115878A0/xx
Priority to ZA959386A priority patent/ZA959386B/xx
Priority to TR95/01400A priority patent/TR199501400A2/xx
Priority to IS4467A priority patent/IS4467A/is
Priority to NO971986A priority patent/NO971986D0/no
Priority to FI971947A priority patent/FI118511B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/10—Complex coacervation, i.e. interaction of oppositely charged particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Surgical Instruments (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Confectionery (AREA)
  • Soft Magnetic Materials (AREA)
SE9403846A 1994-11-09 1994-11-09 Small particle formation SE9403846D0 (sv)

Priority Applications (27)

Application Number Priority Date Filing Date Title
SE9403846A SE9403846D0 (sv) 1994-11-09 1994-11-09 Small particle formation
BR9509720A BR9509720A (pt) 1994-11-09 1995-11-03 Processo para a preparação de pequenas partículas compreendendo um composto orgânico cuja solubilidade é maior em um primerio solvente miscível em água que em um segundo solvente que é aquoso e uso das pequenas partículas
KR1019970703072A KR970706799A (ko) 1994-11-09 1995-11-03 소립자 형성(Small Partical Formation)
EP95938091A EP0788350B1 (en) 1994-11-09 1995-11-03 Small particle formation
ES95938091T ES2173204T3 (es) 1994-11-09 1995-11-03 Formacion de particulas pequeñas.
US08/553,460 US5780062A (en) 1994-11-09 1995-11-03 Small particle formation
SK559-97A SK55997A3 (en) 1994-11-09 1995-11-03 Small particle formation
PL95320425A PL320425A1 (en) 1994-11-09 1995-11-03 Method of producing small particles
DK95938091T DK0788350T3 (da) 1994-11-09 1995-11-03 Dannelse af små partikler
CZ971295A CZ129597A3 (en) 1994-11-09 1995-11-03 Process for preparing small particles
DE69525639T DE69525639T2 (de) 1994-11-09 1995-11-03 Herstellung kleiner partikel
AU38851/95A AU700644B2 (en) 1994-11-09 1995-11-03 Small particle formation
JP51597096A JP4098827B2 (ja) 1994-11-09 1995-11-03 微細粒子の形成
PCT/SE1995/001302 WO1996014833A1 (en) 1994-11-09 1995-11-03 Small particle formation
EE9700214A EE9700214A (et) 1994-11-09 1995-11-03 Väikeste osakeste moodustamine
NZ295497A NZ295497A (en) 1994-11-09 1995-11-03 Process for producing small organic particles
AT95938091T ATE213625T1 (de) 1994-11-09 1995-11-03 Herstellung kleiner partikel
PT95938091T PT788350E (pt) 1994-11-09 1995-11-03 Formacao de particulas pequenas
CA002203512A CA2203512A1 (en) 1994-11-09 1995-11-03 Small particle formation
HU9800181A HUT77629A (hu) 1994-11-09 1995-11-03 Eljárás kis részecskék előállítására
CN95196084A CN1165478A (zh) 1994-11-09 1995-11-03 微丸的形成
ZA959386A ZA959386B (en) 1994-11-09 1995-11-06 Small particle formation
IL11587895A IL115878A0 (en) 1994-11-09 1995-11-06 Small particle formation
TR95/01400A TR199501400A2 (tr) 1994-11-09 1995-11-09 Kücük partikül meydana getirilmesi
IS4467A IS4467A (is) 1994-11-09 1997-04-21 Myndun smárra agna
NO971986A NO971986D0 (no) 1994-11-09 1997-04-29 Fremgangsmåte for fremstilling av små partikler
FI971947A FI118511B (fi) 1994-11-09 1997-05-07 Pienten partikkelien muodostuminen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9403846A SE9403846D0 (sv) 1994-11-09 1994-11-09 Small particle formation

Publications (1)

Publication Number Publication Date
SE9403846D0 true SE9403846D0 (sv) 1994-11-09

Family

ID=20395907

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9403846A SE9403846D0 (sv) 1994-11-09 1994-11-09 Small particle formation

Country Status (27)

Country Link
US (1) US5780062A (fi)
EP (1) EP0788350B1 (fi)
JP (1) JP4098827B2 (fi)
KR (1) KR970706799A (fi)
CN (1) CN1165478A (fi)
AT (1) ATE213625T1 (fi)
AU (1) AU700644B2 (fi)
BR (1) BR9509720A (fi)
CA (1) CA2203512A1 (fi)
CZ (1) CZ129597A3 (fi)
DE (1) DE69525639T2 (fi)
DK (1) DK0788350T3 (fi)
EE (1) EE9700214A (fi)
ES (1) ES2173204T3 (fi)
FI (1) FI118511B (fi)
HU (1) HUT77629A (fi)
IL (1) IL115878A0 (fi)
IS (1) IS4467A (fi)
NO (1) NO971986D0 (fi)
NZ (1) NZ295497A (fi)
PL (1) PL320425A1 (fi)
PT (1) PT788350E (fi)
SE (1) SE9403846D0 (fi)
SK (1) SK55997A3 (fi)
TR (1) TR199501400A2 (fi)
WO (1) WO1996014833A1 (fi)
ZA (1) ZA959386B (fi)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US7029700B2 (en) * 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
AU2001231000A1 (en) * 2000-01-19 2001-07-31 Pharmaceutical Discovery Corporation Dry powder formulations of antihistamine for nasal administration
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
ATE319432T1 (de) * 2000-12-22 2006-03-15 Baxter Int Verfahren zur herstellung von submikropartikel- suspensionen pharmazeutischer substanzen
US6623761B2 (en) 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
DE10117049A1 (de) * 2001-04-05 2002-10-17 Novartis Ag Zusammensetzung
EP1401399A2 (en) * 2001-06-22 2004-03-31 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
BR0211705A (pt) * 2001-08-06 2004-09-28 Astrazeneca Ab Processo para a preparação de uma dispersão estável de partìculas sólidas em um meio aquoso, dispersão estável aquosa, partìcula sólida, composição farmacêutica, método para a inibição do amadurecimento de ostwald em uma dispersão de partìculas sólidas substancialmente insolúveis em água em um meio aquoso, e, uso de um inibidor
US6746635B2 (en) * 2001-08-08 2004-06-08 Brown University Research Foundation Methods for micronization of hydrophobic drugs
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
BRPI0410767A (pt) * 2003-05-19 2006-07-04 Baxter Int formulações farmacêuticas de partìcula pequena de agentes antiataque e antidemência e agentes imunossupressores
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
EP1641779A1 (en) * 2003-06-18 2006-04-05 AstraZeneca AB 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
EP1663158A2 (en) * 2003-06-24 2006-06-07 Baxter International Inc. Specific delivery of drugs to the brain
AU2004275764B2 (en) 2003-09-22 2010-01-14 Baxter Healthcare S.A. High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
WO2005032511A2 (en) * 2003-09-30 2005-04-14 Spherics, Inc. Nanoparticulate therapeutic biologically active agents
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
EP1713443A2 (en) * 2004-01-29 2006-10-25 Baxter International Inc. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
EP1711163A2 (en) * 2004-02-05 2006-10-18 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
RU2006144851A (ru) * 2004-06-15 2008-06-20 Бакстер Интернэшнл Инк. (Us) Применение терапевтических средств ex-vivo в виде твердых микрочастиц
WO2006034147A2 (en) * 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
CA2723470C (en) * 2007-05-07 2013-12-03 Hale Biopharma Ventures, Llc Nasal administration of benzodiazepines
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
US8974827B2 (en) 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US8101274B2 (en) * 2007-06-11 2012-01-24 Spedden Richard H Solid state membranes with surface-embedded glycosylated amphiphilic molecules and micelles formed therefrom
GB0714223D0 (en) * 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
RU2496482C2 (ru) 2008-03-05 2013-10-27 Бакстер Интернэшнл Инк. Композиции и способы для доставки лекарственных средств
US20090258865A1 (en) * 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
CN101278921B (zh) * 2008-06-03 2010-06-09 海南百那医药发展有限公司 盐酸托烷司琼微囊及其注射剂生产方法
US20100151037A1 (en) * 2008-08-07 2010-06-17 Yivan Jiang Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
CN102176882A (zh) 2008-08-07 2011-09-07 生物活性外科公司 医疗器械和植入物的干细胞捕获和固定涂层
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
CN102784103A (zh) * 2011-05-16 2012-11-21 中国科学院上海药物研究所 一种通过混合胶束技术制备的普罗布考纳米混悬液及其制备方法
WO2012170866A1 (en) * 2011-06-10 2012-12-13 Norac Pharma Benzoyl peroxide microparticle process
CN107737100A (zh) 2011-06-14 2018-02-27 哈尔生物药投资有限责任公司 苯二氮卓组合物的投与
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US20180155290A1 (en) * 2015-05-08 2018-06-07 Davuluri Ramamohan Rao Improved Process for the Preparation of Aripiprazole with Reduced Particle Size

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4606940A (en) * 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
JPH0249720A (ja) * 1988-05-18 1990-02-20 Mitsubishi Kasei Corp 難溶性薬剤組成物
SE464743B (sv) * 1989-06-21 1991-06-10 Ytkemiska Inst Foerfarande foer framstaellning av laekemedelspartiklar
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.

Also Published As

Publication number Publication date
CN1165478A (zh) 1997-11-19
IL115878A0 (en) 1996-01-31
AU700644B2 (en) 1999-01-14
EP0788350B1 (en) 2002-02-27
JP4098827B2 (ja) 2008-06-11
KR970706799A (ko) 1997-12-01
ATE213625T1 (de) 2002-03-15
CZ129597A3 (en) 1997-12-17
US5780062A (en) 1998-07-14
PT788350E (pt) 2002-07-31
IS4467A (is) 1997-04-21
DE69525639D1 (de) 2002-04-04
FI971947A0 (fi) 1997-05-07
NZ295497A (en) 1998-05-27
WO1996014833A1 (en) 1996-05-23
CA2203512A1 (en) 1996-05-23
DK0788350T3 (da) 2002-04-29
ES2173204T3 (es) 2002-10-16
TR199501400A2 (tr) 1996-06-21
PL320425A1 (en) 1997-09-29
FI971947A (fi) 1997-05-07
BR9509720A (pt) 1997-10-21
NO971986L (no) 1997-04-29
NO971986D0 (no) 1997-04-29
HUT77629A (hu) 1998-06-29
EP0788350A1 (en) 1997-08-13
FI118511B (fi) 2007-12-14
EE9700214A (et) 1998-04-15
JPH10508840A (ja) 1998-09-02
ZA959386B (en) 1996-05-09
SK55997A3 (en) 1998-01-14
AU3885195A (en) 1996-06-06
DE69525639T2 (de) 2002-08-29

Similar Documents

Publication Publication Date Title
SE9403846D0 (sv) Small particle formation
DK0787112T3 (da) Aerogelholdig sammensætning, fremgangsmåde til dens fremstilling samt dens anvendelse
DE69528273D1 (de) 1,2-substituierte imidazolylverbindungen zur behandlung von entzündungen
DE69418461T2 (de) Neue 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazol-derivate
ATE390414T1 (de) Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten
ZA959451B (en) 2,2-Dichloroalkanecarboxylic acids process of their production and pharmaceutical agents containing these
FR2689127B1 (fr) Nouvelles 3', 5' -ditertbutyl-4'-hydroxy flavones, leur procede de preparation et les compositions pharmaceutiques les renfermant.
NO973646L (no) Orale doseringsformer inneholdende et <beta>-laktam antibiotikum
DE59208279D1 (de) Lagerstabil verkapseltes natriumpercarbonat und verfahren zu seiner herstellung
DE59208974D1 (de) Neue pyrazinderivative, ihre herstellung und verwendung
FR2663328B1 (fr) Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant.
BG106517A (en) Ciclesonide-containing aqueous pharmaceutical composition
DE69332640D1 (de) Pharmazeutische pyridin-derivate
FI925445A (fi) Foerfarande foer framstaellning av 10b-h-steroider
DE69526519D1 (de) Silylierungsprocess
ATE259817T1 (de) Herstellung von einem clavulansäuresalz
KR850001737A (ko) N,n-디메틸-2-클로로-5-[3-메틸-2-(페닐이미노)-4-티아졸린-4-일]-페닐설폰아미이드의 포합화합물의 제조방법
SE9401596D0 (sv) New compounds
EP1132368A3 (de) Verfahren zur Herstellung von 2-Fluor-1,1-dichlor-acrylsäurechlorid
NO974687L (no) Kondenserte <beta>-carboliner
BG95739A (en) Means for the potentiation of the cyclophosphamide effect in intralesion application in solid malignant tumours